Head and Neck Cancer Clinical Trial Landscape
Data updated: May 20, 2026
1,206 clinical trials tracked since 2008
Head and neck cancer is a group of cancers that start in the squamous cells lining the moist surfaces of the head and neck, such as the mouth, throat, and voice box. Clinical trials are essential for advancing treatment options and improving outcomes for patients affected by these cancers. Since 2008, 1,196 trials have been registered, with 520 currently active, meaning they are recruiting, enrolling, or active but not recruiting. The majority of active trials are in Phase 1 and Phase 2, with 224 and 333 trials respectively, while Phase 3 trials account for 55 active studies. This suggests a strong focus on early-stage drug development and investigation of novel therapeutic approaches. Sichuan Baili Pharmaceutical Co., Ltd. leads industry sponsorship with 8 active trials, followed by AstraZeneca with 6. Rakuten Medical, Inc., Boehringer Ingelheim, and Merus B.V. are also prominent sponsors, each with 4 active trials. The relatively small number of Phase 4 trials (6 active) suggests limited activity in confirmatory studies and long-term outcome research.
519 active
/
1206 total (since 2008)
223
Phase 1 Active
568 total
332
Phase 2 Active
718 total
55
Phase 3 Active
111 total
7
Phase 4 Active
24 total
Top Industry Sponsors
Sorted by active Active Done Failed
Sichuan Baili Pharmaceutical Co., Ltd. 8 0 0
AstraZeneca 6 5 0
Rakuten Medical, Inc. 4 1 2
Merus B.V. 4 0 0
Boehringer Ingelheim 3 1 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06589804 RECRUITING
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI) n=158
NCT05063552 ACTIVE NOT RECRUITING
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI) n=430
NCT06641791 RECRUITING
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
Canadian Cancer Trials Group n=196
NCT07580300 RECRUITING
Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.
Oslo University Hospital n=400
NCT06992427 RECRUITING
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Alliance for Clinical Trials in Oncology n=228
+ 106 more Phase 3 trials — see full database below
Head and Neck Cancer — Trials Started by Year (last 10 years)
2016 40
2017 55
2018 77
2019 80
2020 87
2021 94
2022 82
2023 99
2024 112
2025 101
2026 67
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Sichuan Baili Pharmaceutical Co., Ltd. 8
AstraZeneca 11
Rakuten Medical, Inc. 7
Merus B.V. 4
Boehringer Ingelheim 4
ALX Oncology Inc. 3
Exelixis 3
Pfizer 14
Eli Lilly 5
Seagen, a wholly owned subsidiary of Pfizer 5
Active Trials by Phase
Phase 1 223
Phase 2 332
Phase 3 55
Phase 4 7
Enrollment Size Distribution
1-50 620
51-200 397
201-500 101
501-1k 31
1k+ 5
All Industry Sponsors
Sorted by active Active Done Failed
Sichuan Baili Pharmaceutical Co., Ltd. 8 0 0
AstraZeneca 6 5 0
Rakuten Medical, Inc. 4 1 2
Merus B.V. 4 0 0
Boehringer Ingelheim 3 1 0
ALX Oncology Inc. 3 0 0
Exelixis 3 0 0
Pfizer 2 2 10
Eli Lilly 2 2 1
Seagen, a wholly owned subsidiary of Pfizer 2 2 1
Regeneron 2 0 2
Inhibrx Biosciences, Inc 2 0 1
Johnson & Johnson 2 0 0
USWM CT, LLC 2 0 0
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 2 0 0
NCT06589804 RECRUITING
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI) n=158
NCT05063552 ACTIVE NOT RECRUITING
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI) n=430
NCT06641791 RECRUITING
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
Canadian Cancer Trials Group n=196
NCT07580300 RECRUITING
Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.
Oslo University Hospital n=400
NCT06992427 RECRUITING
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Alliance for Clinical Trials in Oncology n=228
NCT06525220 RECRUITING
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V. n=700
NCT07276399 RECRUITING
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Janssen Research & Development, LLC n=500
NCT06295731 ACTIVE NOT RECRUITING
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Inhibrx Biosciences, Inc n=410
NCT07528495 RECRUITING
A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's
All India Institute of Medical Sciences n=396
NCT05721755 ACTIVE NOT RECRUITING
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
ECOG-ACRIN Cancer Research Group n=290
NCT05815927 RECRUITING
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
European Organisation for Research and Treatment of Cancer - EORTC n=200
NCT07441681 NOT YET RECRUITING
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology n=454
NCT07535567 NOT YET RECRUITING
Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University n=386
NCT04966481 RECRUITING
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
Washington University School of Medicine n=81
NCT01266044 ACTIVE NOT RECRUITING
Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia
M.D. Anderson Cancer Center n=435
NCT04534205 RECRUITING
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
BioNTech SE n=350
NCT07524452 RECRUITING
Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Ming-Yuan Chen n=430
NCT06064877 RECRUITING
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
AVEO Pharmaceuticals, Inc. n=410
NCT06790966 ACTIVE NOT RECRUITING
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
PDS Biotechnology Corp. n=252
NCT07509099 NOT YET RECRUITING
Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC
Ji Dongmei n=316
NCT07467083 RECRUITING
Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy
West China Hospital n=170
NCT06496178 RECRUITING
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
Merus B.V. n=600
NCT03519048 ACTIVE NOT RECRUITING
Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris n=197
NCT06788990 RECRUITING
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Bicara Therapeutics n=650
NCT06129864 RECRUITING
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
AstraZeneca n=1,145
NCT04590963 ACTIVE NOT RECRUITING
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
AstraZeneca n=370
NCT07026474 RECRUITING
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
Universität des Saarlandes n=214
NCT07435324 ACTIVE NOT RECRUITING
A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm n=161
NCT07432087 NOT YET RECRUITING
Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Yue He, MD n=246
NCT04967391 ACTIVE NOT RECRUITING
Tumescence in HNC Skin Graft Reconstruction
University of California, Davis n=58
NCT07371897 NOT YET RECRUITING
Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial
Sun Yat-sen University n=154
NCT07320690 NOT YET RECRUITING
De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University n=356
NCT00956007 ACTIVE NOT RECRUITING
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Radiation Therapy Oncology Group n=702
NCT06699212 RECRUITING
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
Rakuten Medical, Inc. n=412
NCT05273307 RECRUITING
Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy
University of California, San Francisco n=40
NCT03340896 ACTIVE NOT RECRUITING
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT
Groupe Oncologie Radiotherapie Tete et Cou n=256
NCT06082167 ACTIVE NOT RECRUITING
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Exelixis n=600
NCT06492460 RECRUITING
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
Sun Yat-sen University n=422
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT04178174 RECRUITING
Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer
Centre hospitalier de l'Université de Montréal (CHUM) n=360
NCT02998385 ACTIVE NOT RECRUITING
Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)
Groupe Oncologie Radiotherapie Tete et Cou n=342
NCT03576417 ACTIVE NOT RECRUITING
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
Groupe Oncologie Radiotherapie Tete et Cou n=680
NCT02999087 ACTIVE NOT RECRUITING
Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
Groupe Oncologie Radiotherapie Tete et Cou n=707
NCT03769506 ACTIVE NOT RECRUITING
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Rakuten Medical, Inc. n=135
NCT06772428 NOT YET RECRUITING
Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.
Changchun GeneScience Pharmaceutical Co., Ltd. n=96
NCT06719479 NOT YET RECRUITING
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
SUNHO（China）BioPharmaceutical CO., Ltd. n=60
NCT06601335 RECRUITING
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Akeso n=510
NCT04747054 RECRUITING
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
UNICANCER n=102
NCT06647563 NOT YET RECRUITING
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University n=355
NCT06248996 RECRUITING
a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients
Lund University Hospital n=308
NCT03755739 RECRUITING
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT06102395 RECRUITING
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Beijing Tongren Hospital n=272
NCT05980715 RECRUITING
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=324
NCT05044117 RECRUITING
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
Sun Yat-sen University n=220
NCT05050162 SUSPENDED
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NRG Oncology n=1,714
NCT04199104 COMPLETED
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Merck Sharp & Dohme LLC n=511
NCT05523323 COMPLETED
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
Merck Sharp & Dohme LLC n=112
NCT05386550 TERMINATED
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
EMD Serono Research & Development Institute, Inc. n=166
NCT03258554 COMPLETED
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI) n=196
NCT01302834 COMPLETED
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group n=987
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT03358472 COMPLETED
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation n=89
NCT04338399 COMPLETED
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Adlai Nortye Biopharma Co., Ltd. n=487
NCT04459715 TERMINATED
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
EMD Serono Research & Development Institute, Inc. n=730
NCT02358031 COMPLETED
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Merck Sharp & Dohme LLC n=882
NCT05930938 TERMINATED
Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer
Groupe Oncologie Radiotherapie Tete et Cou n=19
NCT01345084 WITHDRAWN
Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab
Eurofarma Laboratorios S.A.
NCT01504815 COMPLETED
Adaptive Radiation Treatment for Head and Neck Cancer
The Netherlands Cancer Institute n=268
NCT03452137 TERMINATED
A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Hoffmann-La Roche n=406
NCT01864850 COMPLETED
Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC
Groupe Oncologie Radiotherapie Tete et Cou n=202
NCT02741570 COMPLETED
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Bristol-Myers Squibb n=947
NCT00820248 COMPLETED
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
NCIC Clinical Trials Group n=320
NCT01520701 COMPLETED
Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy
Centre Francois Baclesse n=125
NCT05364918 COMPLETED
Clinical Study On Acute Radiotherapy-Induced Oral Mucositis In Patients With Locally Advanced Head And Neck Tumors
Affiliated Cancer Hospital & Institute of Guangzhou Medical University n=100
NCT05802290 COMPLETED
NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN
Gruppo Oncologico del Nord-Ovest n=124
NCT04969861 TERMINATED
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Nektar Therapeutics n=1
NCT02997553 COMPLETED
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
Institut de Cancérologie de Lorraine n=744
NCT02105636 COMPLETED
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Bristol-Myers Squibb n=361
NCT04129320 WITHDRAWN
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
MacroGenics
NCT01950689 COMPLETED
NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)
The Christie NHS Foundation Trust n=338
NCT02551159 COMPLETED
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
AstraZeneca n=823
NCT02952586 TERMINATED
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Pfizer n=697
NCT03349710 COMPLETED
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Bristol-Myers Squibb n=74
NCT01427478 COMPLETED
Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck
Centre Leon Berard n=134
NCT01126216 TERMINATED
Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer
University of Erlangen-Nürnberg Medical School n=221
NCT02369874 COMPLETED
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
AstraZeneca n=736
NCT01969877 COMPLETED
A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.
Lund University Hospital n=298
NCT00608205 COMPLETED
Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer
Case Comprehensive Cancer Center n=69
NCT00609284 COMPLETED
Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux
Groupe Oncologie Radiotherapie Tete et Cou n=406
NCT03342352 WITHDRAWN
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
Incyte Corporation
NCT00656513 COMPLETED
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
Radiation Therapy Oncology Group n=196
NCT02715596 COMPLETED
Changes in Body Composition After EPA Supplementation in Head and Neck Patients
Institut Català d'Oncologia n=54
NCT00615420 COMPLETED
A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer
British Columbia Cancer Agency n=106
NCT00716391 COMPLETED
TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello n=519
NCT03386838 WITHDRAWN
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
Bristol-Myers Squibb
NCT03637335 TERMINATED
Comparing Palliative Radiotherapy With or Without Carboplatin
Institut Cancerologie de l'Ouest n=26
NCT00894101 WITHDRAWN
Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation
University of California, Irvine
NCT01156142 COMPLETED
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Alliance for Clinical Trials in Oncology n=155
NCT01545687 WITHDRAWN
CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy
Alliance for Clinical Trials in Oncology
NCT01931150 COMPLETED
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Memorial Sloan Kettering Cancer Center n=11
NCT01161498 TERMINATED
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
BioVex Limited n=5
NCT02303197 COMPLETED
Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis
Tianjin Medical University Cancer Institute and Hospital n=70
NCT01012258 COMPLETED
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects
Merck KGaA, Darmstadt, Germany n=70
NCT01596933 COMPLETED
Effect of Omega-3 Supplements on the Prevention of Cachexia in Head and Neck Cancer Treated With Radio(Chemo)Therapy
General Hospital Groeninge n=91
NCT01086826 COMPLETED
Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Associazione Volontari Pazienti Oncologici n=320
NCT01177956 COMPLETED
A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck
Merck KGaA, Darmstadt, Germany n=73
NCT00911326 TERMINATED
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
Navidea Biopharmaceuticals n=101
NCT01812486 COMPLETED
Dose De-escalation to the Elective Nodal Sites in Head and Neck Cancer
Universitaire Ziekenhuizen KU Leuven n=200
NCT00814359 COMPLETED
Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis
Juravinski Cancer Centre Foundation n=67
NCT00790322 COMPLETED
Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy
Biotec Pharmacon ASA n=130
NCT05136196 RECRUITING
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
National Cancer Institute (NCI)
NCT07492914 RECRUITING
Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma
West China Hospital
NCT05172258 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
NCT07195734 RECRUITING
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
National Cancer Institute (NCI)
NCT06980038 RECRUITING
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
NCT05420948 RECRUITING
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
University of Chicago
NCT04373642 ACTIVE NOT RECRUITING
"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
University of Oklahoma
NCT07572864 RECRUITING
Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC
West China Hospital
NCT04152499 ACTIVE NOT RECRUITING
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Klus Pharma Inc.
NCT06997068 RECRUITING
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Mayo Clinic
NCT07576725 NOT YET RECRUITING
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
NCT07484139 NOT YET RECRUITING
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
UNC Lineberger Comprehensive Cancer Center
NCT06385080 RECRUITING
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Janssen Research & Development, LLC
NCT04414540 ACTIVE NOT RECRUITING
Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients
Trisha Wise-Draper
NCT06660017 NOT YET RECRUITING
Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse
University of Oklahoma
NCT04671667 RECRUITING
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
NCT06380816 RECRUITING
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
NCT04083599 ACTIVE NOT RECRUITING
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NCT06769698 RECRUITING
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
NCT06239194 RECRUITING
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT04403620 ACTIVE NOT RECRUITING
HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer
University of Texas Southwestern Medical Center
NCT07058805 RECRUITING
Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer
Olgun Elicin
NCT02734537 RECRUITING
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
ECOG-ACRIN Cancer Research Group
NCT02270814 ACTIVE NOT RECRUITING
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
NCT06532279 RECRUITING
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
NCT07040956 RECRUITING
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
West China Hospital
NCT02641093 ACTIVE NOT RECRUITING
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Trisha Wise-Draper
NCT07524894 NOT YET RECRUITING
Staph Nasal Decolonization to Improve Function and Feeding
David Palma
NCT06305247 ACTIVE NOT RECRUITING
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT06710756 RECRUITING
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
NCT05358548 RECRUITING
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
NCT07408063 RECRUITING
A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
University Health Network, Toronto
NCT01468896 ACTIVE NOT RECRUITING
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT07554768 NOT YET RECRUITING
Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC
Chen Chunyan
NCT06223568 RECRUITING
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
National Cancer Institute (NCI)
NCT07552558 NOT YET RECRUITING
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Washington University School of Medicine
NCT07419464 RECRUITING
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
Washington University School of Medicine
NCT04114136 RECRUITING
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Dan Zandberg
NCT05108870 ACTIVE NOT RECRUITING
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
University of Chicago
NCT07550972 ENROLLING BY INVITATION
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
Zhejiang Provincial People's Hospital
NCT05985655 RECRUITING
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT07209189 RECRUITING
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07407582 RECRUITING
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
NCT07115043 RECRUITING
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
NCT04080804 ACTIVE NOT RECRUITING
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
Dan Zandberg
NCT03389477 ACTIVE NOT RECRUITING
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
NCT06477692 RECRUITING
Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy
University of Texas Southwestern Medical Center
NCT07361133 NOT YET RECRUITING
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
NCT05910827 RECRUITING
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
NCT07213934 RECRUITING
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
University of Cincinnati
NCT07529873 NOT YET RECRUITING
Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma
Groupe Oncologie Radiotherapie Tete et Cou
NCT05576974 RECRUITING
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
University of Texas Southwestern Medical Center
NCT04895709 RECRUITING
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT05913388 RECRUITING
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Providence Health & Services
NCT05075980 ACTIVE NOT RECRUITING
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Mayo Clinic
NCT04938609 ACTIVE NOT RECRUITING
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
Providence Health & Services
NCT05952934 RECRUITING
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
University of Arkansas
NCT04847466 ACTIVE NOT RECRUITING
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
National Cancer Institute (NCI)
NCT06161545 RECRUITING
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
NCT06959108 RECRUITING
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
Groupe Oncologie Radiotherapie Tete et Cou
NCT06919666 ACTIVE NOT RECRUITING
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
University of Colorado, Denver
NCT03916627 ACTIVE NOT RECRUITING
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
NCT06137274 RECRUITING
Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC
H. Lee Moffitt Cancer Center and Research Institute
NCT05318027 ACTIVE NOT RECRUITING
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
Abramson Cancer Center at Penn Medicine
NCT05980000 ACTIVE NOT RECRUITING
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Washington University School of Medicine
NCT05287113 ACTIVE NOT RECRUITING
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Incyte Biosciences International Sàrl
NCT07465276 RECRUITING
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Dana-Farber Cancer Institute
NCT06535607 RECRUITING
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
AstraZeneca
NCT07491783 NOT YET RECRUITING
Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial
Sichuan Enray Pharmaceutical Sciences Company
NCT07109726 RECRUITING
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
NCT04375384 RECRUITING
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Wake Forest University Health Sciences
NCT06332092 ACTIVE NOT RECRUITING
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Fulgent Pharma LLC.
NCT05269381 RECRUITING
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Mayo Clinic
NCT04585750 RECRUITING
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
NCT07035249 RECRUITING
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors
West China Hospital
NCT06580054 RECRUITING
Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
University of Michigan Rogel Cancer Center
NCT04915183 RECRUITING
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
National Institute on Deafness and Other Communication Disorders (NIDCD)
NCT06627270 RECRUITING
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Case Comprehensive Cancer Center
NCT07065630 RECRUITING
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
University of Chicago
NCT07179315 NOT YET RECRUITING
A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment
University of Chicago
NCT06747585 RECRUITING
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Alentis Therapeutics AG
NCT07447050 RECRUITING
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
NCT06657222 RECRUITING
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
NCT07447570 RECRUITING
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06208826 RECRUITING
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
NCT05977907 RECRUITING
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06047379 RECRUITING
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
NCT06727565 ACTIVE NOT RECRUITING
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Gilead Sciences
NCT05544136 RECRUITING
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT06239220 RECRUITING
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Glenn J. Hanna
NCT03565783 ACTIVE NOT RECRUITING
Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
M.D. Anderson Cancer Center
NCT05414032 RECRUITING
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
University Health Network, Toronto
NCT06855212 ACTIVE NOT RECRUITING
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
H. Lee Moffitt Cancer Center and Research Institute
NCT06096038 RECRUITING
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
UNC Lineberger Comprehensive Cancer Center
NCT07063212 RECRUITING
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT05674396 RECRUITING
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
M.D. Anderson Cancer Center
NCT04868877 ACTIVE NOT RECRUITING
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
NCT07030257 RECRUITING
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
NCT07418034 NOT YET RECRUITING
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
University of Maryland, Baltimore
NCT06995508 RECRUITING
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Roswell Park Cancer Institute
NCT06557889 RECRUITING
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas
Institut Claudius Regaud
NCT06636734 RECRUITING
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Emory University
NCT04862650 ACTIVE NOT RECRUITING
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Marcelo Bonomi
NCT04930432 RECRUITING
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Betta Pharmaceuticals Co., Ltd.
NCT07400094 NOT YET RECRUITING
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
National Medical Research Radiological Centre of the Ministry of Health of Russia
NCT05286060 ACTIVE NOT RECRUITING
Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer
Yonsei University
NCT06052839 RECRUITING
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Dan Zandberg
NCT06289049 RECRUITING
Heavy Strength Training in Head and Neck Cancer Survivors
University of Alberta
NCT05280457 RECRUITING
HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy
Yonsei University
NCT07393477 NOT YET RECRUITING
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma
Sir Run Run Shaw Hospital
NCT07278557 RECRUITING
Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia
UNC Lineberger Comprehensive Cancer Center
NCT07371234 RECRUITING
Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Xiwei XU
NCT07381075 NOT YET RECRUITING
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
West China Hospital
NCT07379424 NOT YET RECRUITING
A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
chen chao Professor
NCT07214987 NOT YET RECRUITING
PDT For Induction Therapy For Head And Neck Cancer
Massachusetts General Hospital
NCT03474497 ACTIVE NOT RECRUITING
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
Megan Daly, MD
NCT02919683 ACTIVE NOT RECRUITING
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
Dana-Farber Cancer Institute
NCT05366166 ACTIVE NOT RECRUITING
Pembrolizumab Plus Olaparib in LA-HNSCC
UNC Lineberger Comprehensive Cancer Center
NCT07151040 RECRUITING
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
One-carbon Therapeutics AB
NCT02769520 ACTIVE NOT RECRUITING
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
Assuntina G. Sacco, MD
NCT06172478 RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT07254585 RECRUITING
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT03468218 ACTIVE NOT RECRUITING
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
Emory University
NCT07363031 ENROLLING BY INVITATION
Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy
Instituto Oncoclinicas
NCT05283226 RECRUITING
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NATCO Pharma Ltd.
NCT07354984 NOT YET RECRUITING
A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sun Yat-sen University
NCT06668961 RECRUITING
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
NCT03546582 ACTIVE NOT RECRUITING
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
RTOG Foundation, Inc.
NCT06194656 RECRUITING
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Shanghai Institute Of Biological Products
NCT05312710 ACTIVE NOT RECRUITING
Safety and Efficacy of APG-157 in Head and Neck Cancer
Aveta Biomics, Inc.
NCT04183166 ACTIVE NOT RECRUITING
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
Transgene
NCT03228667 ACTIVE NOT RECRUITING
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
NCT05522985 ACTIVE NOT RECRUITING
Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
NCT05317000 RECRUITING
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Barbara Burtness
NCT04141449 ACTIVE NOT RECRUITING
A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
Brigham and Women's Hospital
NCT07310771 NOT YET RECRUITING
Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II
Fujian Cancer Hospital
NCT04511078 RECRUITING
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
University of Alabama at Birmingham
NCT06725368 RECRUITING
Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Centre Paul Strauss
NCT04198766 ACTIVE NOT RECRUITING
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
NCT04848116 ACTIVE NOT RECRUITING
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01154920 ACTIVE NOT RECRUITING
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
NCT03347838 ACTIVE NOT RECRUITING
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
University of Colorado, Denver
NCT03556228 RECRUITING
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
NCT06943521 RECRUITING
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
NCT07267286 ACTIVE NOT RECRUITING
Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005）
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06265285 RECRUITING
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
NCT05433116 ACTIVE NOT RECRUITING
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
Universität des Saarlandes
NCT06107686 RECRUITING
A Study of YL202 in Selected Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT04842162 RECRUITING
Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery
Gustave Roussy, Cancer Campus, Grand Paris
NCT07094685 RECRUITING
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
University of Michigan Rogel Cancer Center
NCT05226871 ACTIVE NOT RECRUITING
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Pfizer
NCT04180371 ACTIVE NOT RECRUITING
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
NCT06088381 RECRUITING
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
University of Maryland, Baltimore
NCT02955290 ACTIVE NOT RECRUITING
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
Roswell Park Cancer Institute
NCT04074967 ACTIVE NOT RECRUITING
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Dan Zandberg
NCT02923570 ACTIVE NOT RECRUITING
Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT05902988 RECRUITING
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Volastra Therapeutics, Inc.
NCT04643379 ACTIVE NOT RECRUITING
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Washington University School of Medicine
NCT06597565 RECRUITING
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
H. Lee Moffitt Cancer Center and Research Institute
NCT05706129 RECRUITING
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
ITM Oncologics GmbH
NCT05565417 ACTIVE NOT RECRUITING
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
NCT02994069 ACTIVE NOT RECRUITING
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Susanne Arnold
NCT04370587 RECRUITING
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co. Ltd
NCT05909904 ACTIVE NOT RECRUITING
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
BeiGene
NCT03383094 ACTIVE NOT RECRUITING
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Loren Mell, MD
NCT05044897 ACTIVE NOT RECRUITING
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05054439 ACTIVE NOT RECRUITING
A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05668858 RECRUITING
A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06006169 RECRUITING
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT04273061 RECRUITING
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
British Columbia Cancer Agency
NCT05329532 RECRUITING
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Scancell Ltd
NCT07172802 RECRUITING
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
GI Innovation, Inc.
NCT07136545 RECRUITING
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
Taipei Veterans General Hospital, Taiwan
NCT06682793 RECRUITING
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
NCT03631017 ACTIVE NOT RECRUITING
Imaging With a PET Agent for Detection of Cancers of the Head and Neck
Memorial Sloan Kettering Cancer Center
NCT03070366 ACTIVE NOT RECRUITING
Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC
Groupe Oncologie Radiotherapie Tete et Cou
NCT06989671 NOT YET RECRUITING
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT06145412 ACTIVE NOT RECRUITING
A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT06856213 RECRUITING
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
NCT05446467 RECRUITING
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
Zhejiang Provincial People's Hospital
NCT05864144 ACTIVE NOT RECRUITING
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
NCT05608876 ACTIVE NOT RECRUITING
A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer
QBiotics Group Limited
NCT07105592 RECRUITING
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma
Fudan University
NCT04675333 ACTIVE NOT RECRUITING
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
ALX Oncology Inc.
NCT04675294 ACTIVE NOT RECRUITING
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
ALX Oncology Inc.
NCT07090317 RECRUITING
Iparomlimab and Tuvonralimab in HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT05586100 ACTIVE NOT RECRUITING
Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT07088211 RECRUITING
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT04609280 ACTIVE NOT RECRUITING
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
University of Maryland, Baltimore
NCT07090707 NOT YET RECRUITING
PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT07059221 RECRUITING
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06935188 RECRUITING
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT06990737 RECRUITING
Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
University of California, Davis
NCT03247712 ACTIVE NOT RECRUITING
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer
Providence Health & Services
NCT07055841 RECRUITING
Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Xiuping Ding
NCT04868162 RECRUITING
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Shanghai Miracogen Inc.
NCT05286294 ACTIVE NOT RECRUITING
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders
Oslo University Hospital
NCT05272696 RECRUITING
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC
Guangdong Provincial People's Hospital
NCT06580002 RECRUITING
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
NCT05726370 RECRUITING
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Dana-Farber Cancer Institute
NCT04305795 ACTIVE NOT RECRUITING
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Rakuten Medical, Inc.
NCT03341936 ACTIVE NOT RECRUITING
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
Dana-Farber Cancer Institute
NCT07010120 RECRUITING
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
West China Hospital
NCT06952868 RECRUITING
Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers
China Medical University Hospital
NCT04946968 ACTIVE NOT RECRUITING
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
National Cancer Centre, Singapore
NCT04340258 ACTIVE NOT RECRUITING
Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC
University of Cincinnati
NCT06494995 RECRUITING
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
Fudan University
NCT06823479 RECRUITING
Towards Cure Via Only Ultra-short ICB in CSCC
The Netherlands Cancer Institute
NCT06978829 RECRUITING
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NCT03406247 RECRUITING
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris
NCT06437522 RECRUITING
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT03726775 ACTIVE NOT RECRUITING
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
Groupe Oncologie Radiotherapie Tete et Cou
NCT05527782 ACTIVE NOT RECRUITING
Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Hospital Universitario Doctor Peset
NCT06482307 NOT YET RECRUITING
Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET
University Medical Center Groningen
NCT06673693 RECRUITING
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
Sun Yat-sen University
NCT04651634 ACTIVE NOT RECRUITING
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
MitoImmune Therapeutics
NCT03646461 ACTIVE NOT RECRUITING
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
University of California, San Diego
NCT04969315 RECRUITING
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Portage Biotech
NCT06875791 NOT YET RECRUITING
Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients.
Fundacion Clinica Valle del Lili
NCT06690216 ENROLLING BY INVITATION
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
Man Hu
NCT05784688 RECRUITING
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
TiumBio Co., Ltd.
NCT06693323 RECRUITING
Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
University of California, Irvine
NCT04291105 RECRUITING
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad, Inc.
NCT06895369 NOT YET RECRUITING
The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC
Sir Run Run Shaw Hospital
NCT05473156 RECRUITING
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
AP Biosciences Inc.
NCT05835804 NOT YET RECRUITING
Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers
Centre Hospitalier Universitaire, Amiens
NCT04802876 ACTIVE NOT RECRUITING
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
SOLTI Breast Cancer Research Group
NCT06781567 RECRUITING
Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
HitGen Inc.
NCT06869473 RECRUITING
Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.
Gruppo Oncologico del Nord-Ovest
NCT06876844 RECRUITING
Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT05784012 RECRUITING
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
NCT04191460 RECRUITING
Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer
Erasmus Medical Center
NCT06494943 RECRUITING
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
Fudan University
NCT03085719 ACTIVE NOT RECRUITING
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
Dana-Farber Cancer Institute
NCT01220583 ACTIVE NOT RECRUITING
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Radiation Therapy Oncology Group
NCT06470217 RECRUITING
Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT06814067 NOT YET RECRUITING
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Fudan University
NCT06797986 NOT YET RECRUITING
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.
Cellid Co., Ltd.
NCT03526835 RECRUITING
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
NCT04857164 RECRUITING
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
Yuankai Shi
NCT03708224 RECRUITING
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Alain Algazi
NCT06793761 NOT YET RECRUITING
A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC
Beijing Tongren Hospital
NCT06782555 RECRUITING
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
ImmunoGenesis
NCT06087614 RECRUITING
Dose Escalation Using Hypoxia-adjusted Radiotherapy
Rajiv Gandhi Cancer Institute & Research Center, India
NCT06640725 RECRUITING
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
Groupe Oncologie Radiotherapie Tete et Cou
NCT06422403 RECRUITING
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
National University Hospital, Singapore
NCT05877430 RECRUITING
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience, Inc.
NCT06016920 RECRUITING
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Nykode Therapeutics ASA
NCT06725498 RECRUITING
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
Beijing Tongren Hospital
NCT04843098 ACTIVE NOT RECRUITING
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Suzhou Junde Biotechnology Co., Ltd
NCT06714266 NOT YET RECRUITING
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Shandong Cancer Hospital and Institute
NCT06444009 RECRUITING
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Lei Liu
NCT06699498 NOT YET RECRUITING
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
The First Affiliated Hospital with Nanjing Medical University
NCT05878288 ACTIVE NOT RECRUITING
Deep sequencIng in Cutaneous Squamous CEll caRciNomas
Peter MacCallum Cancer Centre, Australia
NCT06648096 RECRUITING
Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
NCT06694350 NOT YET RECRUITING
Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC
Zhejiang Provincial People's Hospital
NCT04787042 RECRUITING
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18, Inc.
NCT03813836 ACTIVE NOT RECRUITING
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC
University College, London
NCT04452032 ACTIVE NOT RECRUITING
Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer
Jules Bordet Institute
NCT05156060 RECRUITING
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
Natalie Lockney
NCT05286619 RECRUITING
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
University of Malaya
NCT05620134 ACTIVE NOT RECRUITING
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
NCT04913337 ACTIVE NOT RECRUITING
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
NCT06137378 RECRUITING
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
University of Leipzig
NCT06578871 NOT YET RECRUITING
Surgery and Reducing Ionizing Radiation of the Unknown Primary
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT06572514 RECRUITING
De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC
Ruijin Hospital
NCT05229614 RECRUITING
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
CNAO National Center of Oncological Hadrontherapy
NCT06007729 RECRUITING
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Hansoh BioMedical R&D Company
NCT05182866 ACTIVE NOT RECRUITING
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
Rakuten Medical, Inc.
NCT06100497 RECRUITING
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
Beijing Tongren Hospital
NCT06537011 NOT YET RECRUITING
AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT06534762 RECRUITING
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Zhejiang Provincial People's Hospital
NCT06530914 NOT YET RECRUITING
A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma
Lei Liu
NCT06509997 NOT YET RECRUITING
A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell Carcinoma
Lei Liu
NCT06505551 NOT YET RECRUITING
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
SCG Cell Therapy Pte. Ltd.
NCT03283605 ACTIVE NOT RECRUITING
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
Centre hospitalier de l'Université de Montréal (CHUM)
NCT06378177 ACTIVE NOT RECRUITING
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Lyvgen Biopharma Holdings Limited
NCT05187338 RECRUITING
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT05060432 ACTIVE NOT RECRUITING
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
iTeos Belgium SA
NCT05955105 RECRUITING
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
NCT06353685 RECRUITING
De-Escalation Postoperative Radiotherapy for Oral Squamous Cell Carcinoma With pCR/MPR.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06323369 RECRUITING
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06366945 NOT YET RECRUITING
Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06360978 NOT YET RECRUITING
Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer
Assiut University
NCT06345287 RECRUITING
Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05773079 NOT YET RECRUITING
Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University
NCT06265025 RECRUITING
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
GeneMedicine Co., Ltd.
NCT05280314 RECRUITING
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
IO Biotech
NCT06022757 RECRUITING
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Evopoint Biosciences Inc.
NCT06240689 RECRUITING
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06199271 NOT YET RECRUITING
Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma
Zhongzheng Xiang
NCT06170710 RECRUITING
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT04989725 RECRUITING
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer
Centre hospitalier de l'Université de Montréal (CHUM)
NCT03691714 ACTIVE NOT RECRUITING
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Trisha Wise-Draper
NCT04729543 RECRUITING
MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
Erasmus Medical Center
NCT06081673 RECRUITING
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT05777824 RECRUITING
Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT03865277 NOT YET RECRUITING
Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging
Technische Universität Dresden
NCT05980702 RECRUITING
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06016413 NOT YET RECRUITING
Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05993858 NOT YET RECRUITING
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT03997643 RECRUITING
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT05941338 RECRUITING
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04807140 RECRUITING
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05343325 RECRUITING
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
Fifth Affiliated Hospital, Sun Yat-Sen University
NCT05595590 RECRUITING
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT04681469 RECRUITING
Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC
Gruppo Oncologico del Nord-Ovest
NCT05025813 RECRUITING
Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma
Queensland Health
NCT04220749 RECRUITING
Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT07589049 NOT YET RECRUITING
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
Sun Yat-sen University
NCT07586124 NOT YET RECRUITING
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
Lepu Biopharma Co., Ltd.
NCT02841748 COMPLETED
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
University of Chicago
NCT04369937 COMPLETED
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
Dan Zandberg
NCT02296684 COMPLETED
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
NCT04313504 COMPLETED
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
Trisha Wise-Draper
NCT03355560 COMPLETED
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
Trisha Wise-Draper
NCT04665843 COMPLETED
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
Hoffmann-La Roche
NCT03650764 COMPLETED
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
NCT05213884 COMPLETED
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Chongqing University Cancer Hospital
NCT03625323 COMPLETED
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Immutep S.A.S.
NCT03574792 COMPLETED
Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy
Roswell Park Cancer Institute
NCT04704453 COMPLETED
Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.
Institut Claudius Regaud
NCT04799054 TERMINATED
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma Oncology Division A/S
NCT05077709 COMPLETED
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
IO Biotech
NCT03370276 COMPLETED
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05673577 COMPLETED
Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients
Fudan University
NCT03744468 COMPLETED
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
NCT03386357 TERMINATED
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
NCT03217188 COMPLETED
Proton Re-Irradiation for Recurrent Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT04883281 COMPLETED
A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer
University of Texas Southwestern Medical Center
NCT01612351 COMPLETED
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
NCT04609566 COMPLETED
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT03313804 COMPLETED
Priming Immunotherapy in Advanced Disease With Radiation
John L. Villano, MD, PhD
NCT02031250 COMPLETED
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
University of Michigan Rogel Cancer Center
NCT03953976 COMPLETED
INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy
University of Texas Southwestern Medical Center
NCT03480672 COMPLETED
Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Leipzig
NCT03993353 COMPLETED
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
NCT02499328 COMPLETED
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
AstraZeneca
NCT05551117 TERMINATED
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
MacroGenics
NCT05814666 TERMINATED
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Flamingo Therapeutics NV
NCT03082534 COMPLETED
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
NCT04862455 TERMINATED
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
NCT04139057 COMPLETED
EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC
Xinqiao Hospital of Chongqing
NCT04169074 TERMINATED
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
University of Arizona
NCT04260802 TERMINATED
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
NCT04326257 COMPLETED
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
Dan Zandberg
NCT04997902 COMPLETED
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Kura Oncology, Inc.
NCT05668949 WITHDRAWN
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
NCT05001347 COMPLETED
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
NCT04811027 COMPLETED
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
Immutep S.A.S.
NCT04428151 COMPLETED
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Merck Sharp & Dohme LLC
NCT04779151 TERMINATED
Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
Gustave Roussy, Cancer Campus, Grand Paris
NCT05383170 COMPLETED
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
Cytovation AS
NCT01927744 COMPLETED
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
M.D. Anderson Cancer Center
NCT04854499 TERMINATED
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Gilead Sciences
NCT04454489 COMPLETED
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
Wake Forest University Health Sciences
NCT06804850 WITHDRAWN
Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
West China Hospital
NCT02369458 COMPLETED
Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Washington University School of Medicine
NCT05169437 TERMINATED
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Tempus AI
NCT04220866 COMPLETED
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
Merck Sharp & Dohme LLC
NCT03049618 COMPLETED
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
University of Southern California
NCT06046482 TERMINATED
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
NCT03821272 COMPLETED
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients
University of Arkansas
NCT04260126 COMPLETED
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
PDS Biotechnology Corp.
NCT00875849 COMPLETED
Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer
Centre Antoine Lacassagne
NCT05271604 COMPLETED
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
BioAtla, Inc.
NCT05061420 TERMINATED
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Sanofi
NCT05459129 COMPLETED
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Hoffmann-La Roche
NCT05323656 COMPLETED
A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Calliditas Therapeutics Suisse SA
NCT05259696 COMPLETED
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Palleon Pharmaceuticals, Inc.
NCT05007106 COMPLETED
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Merck Sharp & Dohme LLC
NCT02327078 COMPLETED
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
NCT00665392 COMPLETED
Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT05517330 COMPLETED
Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma
West China Hospital
NCT05156970 COMPLETED
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT03795610 COMPLETED
IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
Assuntina G. Sacco, MD
NCT05714553 TERMINATED
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
NCT04247282 COMPLETED
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
National Cancer Institute (NCI)
NCT05563272 TERMINATED
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Telix Pharmaceuticals (Innovations) Pty Ltd
NCT05879484 WITHDRAWN
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
National Cancer Institute (NCI)
NCT03440437 TERMINATED
A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
invoX Pharma Limited
NCT04282109 COMPLETED
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
NCT03645928 TERMINATED
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
NCT04616196 COMPLETED
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Nektar Therapeutics
NCT03317327 COMPLETED
REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors
Oslo University Hospital
NCT05499065 COMPLETED
Real-time Margin Assessment in Head and Neck Cancer
University Medical Center Groningen
NCT06251050 COMPLETED
A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy
West China Hospital
NCT04442126 TERMINATED
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
NCT05516589 COMPLETED
Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC
West China Hospital
NCT04555837 COMPLETED
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
NCT03944915 COMPLETED
De-Escalation Therapy for Human Papillomavirus Negative Disease
University of Chicago
NCT04633278 TERMINATED
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
NCT04278092 COMPLETED
Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure
Medical University of Vienna
NCT03212469 COMPLETED
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
Gustave Roussy, Cancer Campus, Grand Paris
NCT03107182 COMPLETED
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
University of Chicago
NCT00942734 COMPLETED
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
NCT04752384 COMPLETED
Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients
Medical College of Wisconsin
NCT04383210 TERMINATED
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
NCT03829501 TERMINATED
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
NCT03754933 COMPLETED
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
GeoVax, Inc.
NCT03602911 COMPLETED
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
West Virginia University
NCT05743270 WITHDRAWN
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Replimune, Inc.
NCT02289209 COMPLETED
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Dan Zandberg
NCT03058289 COMPLETED
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Intensity Therapeutics, Inc.
NCT03169764 WITHDRAWN
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
NCT04357873 COMPLETED
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
UNICANCER
NCT06054477 TERMINATED
Study of ALE.C04 in Patients With Head and Neck Cancer
Alentis Therapeutics AG
NCT04666688 COMPLETED
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
NCT03518606 COMPLETED
Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
UNICANCER
NCT03504488 COMPLETED
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
BioAtla, Inc.
NCT04815720 COMPLETED
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Vaccinex Inc.
NCT02573493 COMPLETED
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Washington University School of Medicine
NCT05500508 TERMINATED
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
NCT03997968 COMPLETED
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
NCT03946358 COMPLETED
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
Centre Hospitalier Universitaire de Besancon
NCT02538510 COMPLETED
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
University of Washington
NCT03878979 COMPLETED
Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04220775 TERMINATED
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
NCT02609503 COMPLETED
Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
UNC Lineberger Comprehensive Cancer Center
NCT05265013 TERMINATED
ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases
Rakuten Medical, Inc.
NCT03153982 TERMINATED
Ruxolitinib in Operable Head and Neck Cancer
University of California, San Francisco
NCT00868491 COMPLETED
Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer
Institute of Oncology Ljubljana
NCT04144517 COMPLETED
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
Mural Oncology, Inc
NCT03207867 TERMINATED
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis Pharmaceuticals
NCT03565003 COMPLETED
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
Jacobio Pharmaceuticals Co., Ltd.
NCT03521570 COMPLETED
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
Emory University
NCT04474470 COMPLETED
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
TyrNovo Ltd.
NCT04721223 COMPLETED
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT03422536 COMPLETED
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
University of Arizona
NCT05724602 SUSPENDED
Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC
NCT02777385 COMPLETED
Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
Dan Zandberg
NCT02776163 COMPLETED
Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT06084845 WITHDRAWN
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
ECOG-ACRIN Cancer Research Group
NCT04570839 COMPLETED
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Compugen Ltd
NCT04541355 COMPLETED
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
Hyunseok Kang, MD
NCT03719690 COMPLETED
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
Kura Oncology, Inc.
NCT06446570 COMPLETED
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Seoul National University Hospital
NCT03494322 COMPLETED
EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer
University College, London
NCT04939480 COMPLETED
Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN
University Hospital, Essen
NCT03723967 COMPLETED
FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel
Centre Leon Berard
NCT03426657 COMPLETED
Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC
University of Erlangen-Nürnberg Medical School
NCT04936841 TERMINATED
Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma
University of Wisconsin, Madison
NCT03665285 COMPLETED
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
NCT05099549 TERMINATED
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
NKGen Biotech, Inc.
NCT01979211 COMPLETED
Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
University of Cincinnati
NCT04221165 COMPLETED
Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT01330446 COMPLETED
Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer
M.D. Anderson Cancer Center
NCT05918224 COMPLETED
Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy
West China Hospital
NCT01437449 COMPLETED
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Stanford University
NCT03543813 COMPLETED
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
CytomX Therapeutics
NCT03511391 COMPLETED
CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors
University Hospital, Ghent
NCT05724849 WITHDRAWN
Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer
Vanderbilt University Medical Center
NCT03149549 TERMINATED
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
CytomX Therapeutics
NCT04634825 TERMINATED
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
MacroGenics
NCT03894891 COMPLETED
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
Dana-Farber Cancer Institute
NCT05363605 TERMINATED
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Fusion Pharmaceuticals Inc.
NCT06090318 WITHDRAWN
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
NCT01711658 COMPLETED
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
Radiation Therapy Oncology Group
NCT03267121 COMPLETED
A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT03083873 COMPLETED
Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Iovance Biotherapeutics, Inc.
NCT04193293 TERMINATED
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
SecuraBio
NCT05359692 WITHDRAWN
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Incyte Biosciences International Sàrl
NCT04834349 WITHDRAWN
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
NCT05535023 WITHDRAWN
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
M.D. Anderson Cancer Center
NCT02524275 TERMINATED
Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
University of Nebraska
NCT02499120 COMPLETED
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Pfizer
NCT05110781 TERMINATED
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
Arnaud Bewley, MD
NCT03624231 COMPLETED
Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC
Ulrich Keilholz
NCT00707655 TERMINATED
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
Genmab
NCT01054625 COMPLETED
Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Genmab
NCT03602079 COMPLETED
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
NCT04424641 TERMINATED
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Genmab
NCT02207439 COMPLETED
Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Abramson Cancer Center at Penn Medicine
NCT03740100 TERMINATED
Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
M.D. Anderson Cancer Center
NCT03735680 COMPLETED
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
OncoNano Medicine, Inc.
NCT02949700 COMPLETED
Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
Baylor College of Medicine
NCT01084083 COMPLETED
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
NCT01824823 TERMINATED
Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence
ECOG-ACRIN Cancer Research Group
NCT02488629 TERMINATED
Study of SCB01A in Patient With Head and Neck Cancer
SynCore Biotechnology Co., Ltd.
NCT03522584 TERMINATED
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Washington
NCT01711541 COMPLETED
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
NCT04987996 WITHDRAWN
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Providence Health & Services
NCT02057107 COMPLETED
SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN
Heath Skinner
NCT05743777 WITHDRAWN
PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma
Canadian Cancer Trials Group
NCT02345330 TERMINATED
Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)
OncoSec Medical Incorporated
NCT03823131 TERMINATED
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
Chase Heaton, MD
NCT02823574 COMPLETED
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Bristol-Myers Squibb
NCT03254927 TERMINATED
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Celldex Therapeutics
NCT04208334 COMPLETED
The Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer
Phramongkutklao College of Medicine and Hospital
NCT04034225 TERMINATED
Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN
Sensei Biotherapeutics, Inc.
NCT02291055 TERMINATED
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
Advaxis, Inc.
NCT02990468 COMPLETED
A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
BioMimetix JV, LLC
NCT02126969 COMPLETED
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
Susanne Arnold
NCT03435640 TERMINATED
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Nektar Therapeutics
NCT00702481 COMPLETED
Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer
National Cancer Centre, Singapore
NCT02707588 COMPLETED
Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC
Groupe Oncologie Radiotherapie Tete et Cou
NCT03356223 COMPLETED
Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6
Centre Leon Berard
NCT01173172 COMPLETED
Boron Neutron Capture Therapy (BNCT) for Locally Recurrent Head and Neck Cancer
Taipei Veterans General Hospital, Taiwan
NCT04685499 TERMINATED
Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease
Weill Medical College of Cornell University
NCT03982537 WITHDRAWN
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
Wake Forest University Health Sciences
NCT02643303 COMPLETED
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
NCT01874860 COMPLETED
Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
University of Louisville
NCT03620123 COMPLETED
A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck
AIO-Studien-gGmbH
NCT03405142 COMPLETED
Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
Eben Rosenthal
NCT04242173 TERMINATED
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
H. Lee Moffitt Cancer Center and Research Institute
NCT02965001 COMPLETED
Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer
Rigshospitalet, Denmark
NCT02055963 TERMINATED
Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer
M.D. Anderson Cancer Center
NCT01458392 COMPLETED
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
NCT02002182 COMPLETED
ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Andrew Sikora
NCT01592721 COMPLETED
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
The University of Texas Health Science Center at San Antonio
NCT03162224 COMPLETED
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
MedImmune LLC
NCT02268695 COMPLETED
Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC
Groupe Oncologie Radiotherapie Tete et Cou
NCT04529850 COMPLETED
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
Galera Therapeutics, Inc.
NCT04831450 WITHDRAWN
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Miami
NCT04849377 WITHDRAWN
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
Icahn School of Medicine at Mount Sinai
NCT03057613 COMPLETED
The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Case Comprehensive Cancer Center
NCT02255097 COMPLETED
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Merck Sharp & Dohme LLC
NCT04880603 TERMINATED
Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site
Nebraska Methodist Health System
NCT03633110 COMPLETED
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Genocea Biosciences, Inc.
NCT05234606 WITHDRAWN
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Silverback Therapeutics
NCT03684785 TERMINATED
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Exicure, Inc.
NCT04428047 TERMINATED
Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma
UNICANCER
NCT03292250 COMPLETED
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
NCT03067610 COMPLETED
Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
University of Texas Southwestern Medical Center
NCT03330249 COMPLETED
Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion
Groupe Oncologie Radiotherapie Tete et Cou
NCT02684253 COMPLETED
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT01606566 TERMINATED
A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.
PCI Biotech AS
NCT02178722 COMPLETED
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
NCT02318277 COMPLETED
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
Incyte Corporation
NCT02901483 TERMINATED
A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
PharmaEngine
NCT03829007 COMPLETED
PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC
Radboud University Medical Center
NCT03937141 TERMINATED
Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer
Chinook Therapeutics, Inc. (formerly Aduro)
NCT01332266 COMPLETED
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Eisai Inc.
NCT02001623 COMPLETED
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Seagen Inc.
NCT04408898 WITHDRAWN
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
Adaptimmune
NCT03245736 COMPLETED
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Seagen Inc.
NCT03096808 COMPLETED
Adaptive Radiotherapy for Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT02085460 COMPLETED
A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer
Otsuka Pharmaceutical Co., Ltd.
NCT04052204 TERMINATED
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Pfizer
NCT04607642 WITHDRAWN
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
BioMimetix JV, LLC
NCT03938337 TERMINATED
Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer
University of Alabama at Birmingham
NCT03101514 COMPLETED
Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study
First Affiliated Hospital of Harbin Medical University
NCT04464967 WITHDRAWN
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
NCT02762513 COMPLETED
Expansion Trial for Axitinib In Head And Neck Cancer
University of Michigan Rogel Cancer Center
NCT03194373 COMPLETED
Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Michigan Rogel Cancer Center
NCT01126008 COMPLETED
Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer
Samsung Medical Center
NCT02759575 COMPLETED
A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
Vinita Takiar
NCT01620242 COMPLETED
A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes
UNICANCER
NCT01716195 COMPLETED
Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer
University of California, Davis
NCT00904345 TERMINATED
Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)
University of Michigan Rogel Cancer Center
NCT03887442 TERMINATED
Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
NCT01602315 TERMINATED
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Novartis Pharmaceuticals
NCT02423863 COMPLETED
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Oncovir, Inc.
NCT01689194 COMPLETED
Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer
Seoul National University Hospital
NCT03655444 TERMINATED
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Washington University School of Medicine
NCT01412229 COMPLETED
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
UNC Lineberger Comprehensive Cancer Center
NCT04262388 WITHDRAWN
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
University Health Network, Toronto
NCT03349034 COMPLETED
Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps
Icahn School of Medicine at Mount Sinai
NCT01386632 COMPLETED
Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma
Sanford Health
NCT02207530 COMPLETED
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
NCT00736944 COMPLETED
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
Washington University School of Medicine
NCT04058145 WITHDRAWN
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
Massachusetts General Hospital
NCT04093115 WITHDRAWN
Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Beijing Konruns Pharmaceutical Co., Ltd.
NCT04525066 COMPLETED
Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma
Ayhman Al Afif
NCT00833261 COMPLETED
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
University of Texas Southwestern Medical Center
NCT00851877 COMPLETED
Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer
University of Texas Southwestern Medical Center
NCT02124707 COMPLETED
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
UNC Lineberger Comprehensive Cancer Center
NCT02842125 TERMINATED
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
MultiVir, Inc.
NCT01133678 TERMINATED
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
University of Chicago
NCT03433027 COMPLETED
A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Benitec Biopharma, Inc.
NCT00721513 COMPLETED
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Wake Forest University Health Sciences
NCT00957853 COMPLETED
Preoperative Treatment With Cetuximab and/or IMC-A12
M.D. Anderson Cancer Center
NCT01044433 COMPLETED
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Abramson Cancer Center at Penn Medicine
NCT02452424 TERMINATED
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Daiichi Sankyo
NCT01697800 COMPLETED
A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02422979 COMPLETED
Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer
Rakuten Medical, Inc.
NCT01744340 COMPLETED
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
howard safran
NCT02882308 COMPLETED
Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.
Hellenic Cooperative Oncology Group
NCT03323424 WITHDRAWN
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers
Institut de Cancérologie de la Loire
NCT03463161 TERMINATED
Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy
University of Chicago
NCT01998542 COMPLETED
Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck
Mirror Biologics, Inc.
NCT02335918 COMPLETED
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Celldex Therapeutics
NCT01774760 COMPLETED
Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer
Turku University Hospital
NCT02454179 COMPLETED
Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma
Acerta Pharma BV
NCT01581970 COMPLETED
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
Masonic Cancer Center, University of Minnesota
NCT01016769 COMPLETED
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT02410382 TERMINATED
Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer
University of Arizona
NCT03325465 WITHDRAWN
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
University of Chicago
NCT01264328 COMPLETED
Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
NCT02706691 TERMINATED
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
University of Chicago
NCT00765011 COMPLETED
TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
NCT02946021 COMPLETED
Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema
Tactile Medical
NCT03114280 WITHDRAWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)
Centre Antoine Lacassagne
NCT00750555 TERMINATED
Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Geisinger Clinic
NCT02976883 COMPLETED
[18F]HX4 PET/CT Imaging for Detection of Hypoxia
Nottingham University Hospitals NHS Trust
NCT00573989 TERMINATED
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Wake Forest University Health Sciences
NCT01696955 COMPLETED
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03246685 TERMINATED
Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
HiberCell, Inc.
NCT00756444 COMPLETED
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Amgen
NCT00896454 COMPLETED
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
NCT01653327 COMPLETED
Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer
Dartmouth-Hitchcock Medical Center
NCT01218048 COMPLETED
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
Robert Ferris
NCT01732640 TERMINATED
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01852292 TERMINATED
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Novartis Pharmaceuticals
NCT01009346 TERMINATED
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00646659 TERMINATED
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
European Organisation for Research and Treatment of Cancer - EORTC
NCT00617734 COMPLETED
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
Eli Lilly and Company
NCT01984892 TERMINATED
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
Nina Bhardwaj
NCT01488318 TERMINATED
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
Julie E. Bauman, MD, MPH
NCT03238638 WITHDRAWN
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
University of Chicago
NCT01221753 TERMINATED
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
Dana-Farber Cancer Institute
NCT01237483 COMPLETED
Reirradiation and Erbitux in the HNSCC
Groupe Oncologie Radiotherapie Tete et Cou
NCT02135185 COMPLETED
Effect of the Rehabilitation Effort at Home in Patients With Head and Neck Tumor Treated With Curative Intent
Institut du Cancer de Montpellier - Val d'Aurelle
NCT01733823 COMPLETED
DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole
Danish Head and Neck Cancer Group
NCT00704639 COMPLETED
Chemoradiation Treatment for Head and Neck Cancer
Trans Tasman Radiation Oncology Group
NCT01528163 COMPLETED
Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
NCT01794845 TERMINATED
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
University of Miami
NCT01467115 COMPLETED
Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer
Drexel University College of Medicine
NCT00927147 TERMINATED
Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer
Boneca Corporation
NCT01040832 COMPLETED
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
EMD Serono
NCT02281006 TERMINATED
Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity
CHU de Quebec-Universite Laval
NCT01577173 COMPLETED
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Genentech, Inc.
NCT01469546 COMPLETED
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
University of Michigan Rogel Cancer Center
NCT01405846 TERMINATED
Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib
Papworth Hospital NHS Foundation Trust
NCT01045421 COMPLETED
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Millennium Pharmaceuticals, Inc.
NCT00968435 COMPLETED
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT01820312 WITHDRAWN
A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)
University of Arkansas
NCT02143622 WITHDRAWN
Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients
Novartis Pharmaceuticals
NCT00872404 TERMINATED
A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
NCT02479178 TERMINATED
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
BIND Therapeutics
NCT01285635 TERMINATED
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
University of Michigan Rogel Cancer Center
NCT02047201 COMPLETED
Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC
Lithuanian University of Health Sciences
NCT02430298 COMPLETED
Topical/Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients
Khon Kaen University
NCT01695122 COMPLETED
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
Instituto do Cancer do Estado de São Paulo
NCT01333085 COMPLETED
Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT01183065 COMPLETED
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT00720083 TERMINATED
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
Radiation Therapy Oncology Group
NCT02061631 COMPLETED
Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck
Sanofi
NCT01312493 WITHDRAWN
Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab
UNC Lineberger Comprehensive Cancer Center
NCT01701466 TERMINATED
Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis
Sir Mortimer B. Davis - Jewish General Hospital
NCT00827164 COMPLETED
Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer
University of Alabama at Birmingham
NCT00713219 COMPLETED
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT00881114 WITHDRAWN
Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer
Georgetown University
NCT01548846 TERMINATED
Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract
Centre Francois Baclesse
NCT01164176 COMPLETED
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Yonsei University
NCT01465308 COMPLETED
The Effect of Honey on Xerostomia and Oral Mucositis
Cyprus University of Technology
NCT01903018 COMPLETED
A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00
Piramal Enterprises Limited
NCT01305772 TERMINATED
Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN
Neal Ready
NCT00918281 COMPLETED
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
NCT01425736 COMPLETED
Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma
Wei Guo
NCT00971932 COMPLETED
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Merck KGaA, Darmstadt, Germany
NCT00959387 COMPLETED
Induction Chemotherapy for Advanced Head and Neck Cancer
Barretos Cancer Hospital
NCT00791141 COMPLETED
Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer
Heinrich-Heine University, Duesseldorf
NCT01172769 COMPLETED
Efficacy Study of Temsirolimus to Treat Head and Neck Cancer
Hannover Medical School
NCT01075399 COMPLETED
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors
Siemens Molecular Imaging
NCT00824343 COMPLETED
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer
Piramal Enterprises Limited
NCT00908024 TERMINATED
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
NCT01245985 TERMINATED
TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors
Heidelberg University
NCT01427205 WITHDRAWN
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
NCT01506427 WITHDRAWN
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
Siemens Molecular Imaging
NCT01015664 TERMINATED
Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
University of Tennessee Cancer Institute
NCT01415986 TERMINATED
Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers
University of Arkansas
NCT00899054 COMPLETED
Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer
Piramal Enterprises Limited
NCT01280318 COMPLETED
Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
NCT00714649 COMPLETED
Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
NCT01213030 COMPLETED
Clinical Evaluation of the New Hypoxia Imaging Agent HX4
Siemens Molecular Imaging
NCT00737360 TERMINATED
Phase II Study of TAS-106 to Treat Head and Neck Cancer
Taiho Pharmaceutical Co., Ltd.
NCT01645748 COMPLETED
Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer
Chonnam National University Hospital
NCT00910117 COMPLETED
Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Fudan University
NCT01313390 TERMINATED
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer
University College, London
NCT00805012 TERMINATED
Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)
Seoul National University Hospital
NCT00756951 COMPLETED
Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer
SciClone Pharmaceuticals
NCT05005403 RECRUITING
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie
NCT07583316 NOT YET RECRUITING
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
NCT07583914 NOT YET RECRUITING
Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors
West China Hospital
NCT05172245 RECRUITING
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
NCT06673329 RECRUITING
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT07156227 NOT YET RECRUITING
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
NCT05877599 RECRUITING
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
NCT07584499 RECRUITING
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
Sun Yat-sen University
NCT06465069 RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06806852 ACTIVE NOT RECRUITING
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Boehringer Ingelheim
NCT05249426 ACTIVE NOT RECRUITING
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Boehringer Ingelheim
NCT05068102 ACTIVE NOT RECRUITING
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Boehringer Ingelheim
NCT07085091 RECRUITING
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ALX Oncology Inc.
NCT05581004 RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT07217028 RECRUITING
Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma
Vanderbilt-Ingram Cancer Center
NCT07567235 RECRUITING
Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis
West China Hospital
NCT04389632 RECRUITING
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05747625 RECRUITING
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Eben Rosenthal
NCT07219212 RECRUITING
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Johnson & Johnson Enterprise Innovation Inc.
NCT07101432 RECRUITING
Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)
M.D. Anderson Cancer Center
NCT07040072 RECRUITING
Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC
Beijing Tongren Hospital
NCT02495896 ACTIVE NOT RECRUITING
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
NCT03803774 ACTIVE NOT RECRUITING
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
NCT07545967 RECRUITING
Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy
West China Hospital
NCT06147037 RECRUITING
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT02812524 ACTIVE NOT RECRUITING
Ipilimumab for Head and Neck Cancer Patients
Providence Health & Services
NCT07020117 RECRUITING
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Aktis Oncology, Inc.
NCT05208762 RECRUITING
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06150664 RECRUITING
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
NCT05039801 RECRUITING
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT07455032 RECRUITING
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
Fox Chase Cancer Center
NCT04533750 ACTIVE NOT RECRUITING
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
NCT06238479 ACTIVE NOT RECRUITING
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT05858736 ACTIVE NOT RECRUITING
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
OncoC4, Inc.
NCT07517198 RECRUITING
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT07216105 RECRUITING
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
NCT07090499 RECRUITING
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT04044859 ACTIVE NOT RECRUITING
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM CT, LLC
NCT06451497 RECRUITING
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
NCT06236425 ACTIVE NOT RECRUITING
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
H. Lee Moffitt Cancer Center and Research Institute
NCT05891171 ACTIVE NOT RECRUITING
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences, Inc.
NCT07503808 RECRUITING
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
NCT07501650 RECRUITING
Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer
Thomas Jefferson University
NCT04722523 RECRUITING
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT07457281 RECRUITING
GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study
West China Hospital
NCT05635643 RECRUITING
Study of CHS-114 in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
NCT04007744 ACTIVE NOT RECRUITING
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
NCT04119024 RECRUITING
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Anusha Kalbasi
NCT05176483 RECRUITING
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT06211335 RECRUITING
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
University of California, Davis
NCT07460765 NOT YET RECRUITING
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Vanderbilt-Ingram Cancer Center
NCT07227168 RECRUITING
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma, Inc.
NCT05901545 RECRUITING
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
NCT06868433 RECRUITING
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Emory University
NCT05526924 RECRUITING
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
University of Chicago
NCT07272642 NOT YET RECRUITING
A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
Radiopharm Theranostics, Ltd
NCT06778863 RECRUITING
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics, Inc.
NCT07182149 RECRUITING
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo, Inc.
NCT05820711 ACTIVE NOT RECRUITING
Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy
University of Wisconsin, Madison
NCT05239143 ACTIVE NOT RECRUITING
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics, Inc.
NCT03740256 RECRUITING
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT04754321 RECRUITING
Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
Ohio State University Comprehensive Cancer Center
NCT05983432 RECRUITING
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.
NCT02432963 ACTIVE NOT RECRUITING
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
NCT06997094 RECRUITING
Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer
Mayo Clinic
NCT07348211 RECRUITING
First in Human Study of SIM0610 in Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT05827614 ACTIVE NOT RECRUITING
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Boundless Bio, Inc.
NCT07358806 RECRUITING
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
NCT07358884 NOT YET RECRUITING
First in Human Study of QLS5316 in Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06736379 RECRUITING
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
VLP Therapeutics
NCT06515990 RECRUITING
A Study of DM005 in Patients With Advanced Solid Tumors
Doma Biopharmaceutical（Suzhou）Co., Ltd.
NCT05902520 ACTIVE NOT RECRUITING
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
AgonOx, Inc.
NCT07274852 RECRUITING
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05544929 ACTIVE NOT RECRUITING
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis Pharmaceuticals
NCT07232524 RECRUITING
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05327270 ACTIVE NOT RECRUITING
Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions
M.D. Anderson Cancer Center
NCT06022029 RECRUITING
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine, Inc.
NCT02567422 ACTIVE NOT RECRUITING
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
NCT05859074 RECRUITING
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT06159621 ACTIVE NOT RECRUITING
CD40 Agonist and PD-1 Inhibitor in HNSCC
University of Pennsylvania
NCT03983954 ACTIVE NOT RECRUITING
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NCT07081984 RECRUITING
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
Therorna
NCT07106827 RECRUITING
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
NCT06332755 RECRUITING
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
LG Chem
NCT05238883 ACTIVE NOT RECRUITING
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05973487 ACTIVE NOT RECRUITING
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics, Inc.
NCT03589339 ACTIVE NOT RECRUITING
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Nanobiotix
NCT07216833 NOT YET RECRUITING
Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Kyunghee Burkitt, DO, PhD
NCT05783622 RECRUITING
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
NCT05945875 RECRUITING
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
NCT02446249 ACTIVE NOT RECRUITING
Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction
MeiraGTx, LLC
NCT05653882 ACTIVE NOT RECRUITING
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Asher Biotherapeutics, Inc.
NCT05937269 ENROLLING BY INVITATION
Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship
The University of Texas Health Science Center, Houston
NCT05107674 RECRUITING
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
NCT06789172 RECRUITING
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Epkin
NCT07154108 NOT YET RECRUITING
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
Sichuan University
NCT05076760 RECRUITING
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen, Inc.
NCT03170960 ACTIVE NOT RECRUITING
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT04429542 RECRUITING
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
NCT05222932 ACTIVE NOT RECRUITING
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
TILT Biotherapeutics Ltd.
NCT07072325 NOT YET RECRUITING
Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers
West China Hospital
NCT06761937 RECRUITING
Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients
Erasmus Medical Center
NCT05540899 ACTIVE NOT RECRUITING
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
American College of Radiology
NCT03690986 RECRUITING
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Emory University
NCT02474368 ACTIVE NOT RECRUITING
Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
Dana-Farber Cancer Institute
NCT03336606 ACTIVE NOT RECRUITING
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
NCT07036185 NOT YET RECRUITING
A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
Shanghai Bao Pharmaceuticals Co., Ltd.
NCT05704985 ACTIVE NOT RECRUITING
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
NCT06540443 RECRUITING
Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
MegaPro Biomedical Co. Ltd.
NCT05674526 ACTIVE NOT RECRUITING
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
Wugen, Inc.
NCT03498378 ACTIVE NOT RECRUITING
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Kathryn Gold
NCT06446713 RECRUITING
PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer
University Medical Center Groningen
NCT03212404 ACTIVE NOT RECRUITING
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
NCT06741982 RECRUITING
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
West China Hospital
NCT04576091 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
NCT05376553 ENROLLING BY INVITATION
Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Krzysztof Misiukiewicz
NCT04593589 RECRUITING
Submandibular Gland Stem Cell Transplantation
University Medical Center Groningen
NCT05215574 ACTIVE NOT RECRUITING
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NCT05200650 RECRUITING
A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor
IntraGel Therapeutics
NCT06614686 RECRUITING
U87 CAR-T in Patients With Advanced Head and Neck Tumors
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
NCT06259552 RECRUITING
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
SparX Biotech(Jiangsu) Co., Ltd.
NCT05867303 ACTIVE NOT RECRUITING
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
NCT06109207 RECRUITING
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
West China Hospital
NCT02308072 ACTIVE NOT RECRUITING
Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer
University College, London
NCT06383507 NOT YET RECRUITING
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
Zhejiang University
NCT05582590 NOT YET RECRUITING
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
NexImmune Inc.
NCT05698238 NOT YET RECRUITING
Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours
Mabpro, a.s.
NCT07589205 RECRUITING
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
NCT04354246 COMPLETED
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
NCT06870487 TERMINATED
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
NCT06091930 COMPLETED
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
NCT03552718 COMPLETED
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience, Inc.
NCT05983133 TERMINATED
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT04266730 SUSPENDED
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
NCT06974734 TERMINATED
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
Pfizer
NCT03881488 COMPLETED
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
NCT03236935 COMPLETED
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
NCT02819752 TERMINATED
PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Royal Marsden NHS Foundation Trust
NCT06110195 TERMINATED
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
University of Chicago
NCT04234113 TERMINATED
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
SOTIO Biotech AG
NCT01783587 COMPLETED
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
Dana-Farber Cancer Institute
NCT06580938 TERMINATED
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
NCT04042935 COMPLETED
Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC
University of Colorado, Denver
NCT07431645 COMPLETED
Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells
Institute of Oncology Ljubljana
NCT07435311 COMPLETED
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
NCT06546553 TERMINATED
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
NCT05462873 TERMINATED
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT02989064 COMPLETED
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Adaptimmune
NCT04640480 COMPLETED
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
NCT03978689 COMPLETED
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Cue Biopharma
NCT03578406 COMPLETED
HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer
Xinqiao Hospital of Chongqing
NCT04045496 COMPLETED
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT06494189 COMPLETED
Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
West China Hospital
NCT04840472 SUSPENDED
Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
Stanford University
NCT06549816 COMPLETED
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT03381183 COMPLETED
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT06052852 TERMINATED
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
NCT05229601 TERMINATED
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT04215978 COMPLETED
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT04000529 TERMINATED
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Novartis Pharmaceuticals
NCT06056310 TERMINATED
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
EMD Serono Research & Development Institute, Inc.
NCT06285097 TERMINATED
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
NCT06338657 TERMINATED
FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer
University of Southern California
NCT03019003 COMPLETED
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Massachusetts General Hospital
NCT04344795 COMPLETED
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Tempest Therapeutics
NCT04879849 COMPLETED
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
Takeda
NCT04105543 COMPLETED
CLR 131 Combined With Radiation for Head and Neck Cancer
University of Wisconsin, Madison
NCT05605522 TERMINATED
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
3B Pharmaceuticals GmbH
NCT02079324 COMPLETED
Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer
Genexine, Inc.
NCT02475213 COMPLETED
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
MacroGenics
NCT05585034 COMPLETED
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
NCT02903914 COMPLETED
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
NCT04580485 COMPLETED
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
NCT03289962 COMPLETED
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
NCT03991741 TERMINATED
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
Gregory Daniels
NCT03635164 COMPLETED
Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma
University of Colorado, Denver
NCT05432193 TERMINATED
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
NCT05788484 COMPLETED
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
NCT04152018 TERMINATED
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
NCT04121286 COMPLETED
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Allist Pharmaceuticals, Inc.
NCT02318771 COMPLETED
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03524326 COMPLETED
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT03894618 COMPLETED
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
NCT04830592 COMPLETED
A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck
Akamis Bio
NCT03195699 COMPLETED
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Tvardi Therapeutics, Incorporated
NCT05576077 TERMINATED
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Turnstone Biologics, Corp.
NCT04465487 TERMINATED
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
Regeneron Pharmaceuticals
NCT04502888 TERMINATED
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
Shattuck Labs, Inc.
NCT04091867 COMPLETED
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
University of Colorado, Denver
NCT04588038 TERMINATED
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
Hyunseok Kang, MD
NCT05053737 COMPLETED
Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC
University of Colorado, Denver
NCT03518554 COMPLETED
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT04217057 TERMINATED
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
Washington University School of Medicine
NCT04795713 TERMINATED
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Molecular Templates, Inc.
NCT06034860 TERMINATED
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
NCT04096638 COMPLETED
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
invoX Pharma Limited
NCT04870840 COMPLETED
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
M.D. Anderson Cancer Center
NCT03809624 TERMINATED
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Inhibrx Biosciences, Inc
NCT04628780 TERMINATED
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Pfizer
NCT03752398 COMPLETED
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Xencor, Inc.
NCT06357858 WITHDRAWN
ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck
Case Comprehensive Cancer Center
NCT05578820 COMPLETED
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Gene Surgery LLC
NCT05538572 COMPLETED
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
NCT03666273 COMPLETED
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
Bayer
NCT03629756 COMPLETED
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT05061537 TERMINATED
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
NCT04659369 TERMINATED
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
Taizhou Mabtech Pharmaceutical Co.,Ltd
NCT04881045 COMPLETED
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Pfizer
NCT03329950 COMPLETED
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
NCT03590054 COMPLETED
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Rahul Aggarwal
NCT04682431 TERMINATED
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Ikena Oncology
NCT05472506 WITHDRAWN
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
Ikena Oncology
NCT05121948 TERMINATED
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
HiberCell, Inc.
NCT04902027 COMPLETED
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT04624113 TERMINATED
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Washington University School of Medicine
NCT02274155 COMPLETED
Anti-OX40 Antibody in Head and Neck Cancer Patients
Providence Health & Services
NCT04244552 TERMINATED
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
NCT03219268 COMPLETED
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
MacroGenics
NCT03454451 COMPLETED
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
NCT02482168 COMPLETED
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America, Inc.
NCT03525392 TERMINATED
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Ipsen
NCT03229278 COMPLETED
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
NCT04892875 WITHDRAWN
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
Jennifer Choe
NCT01332682 COMPLETED
Resistance Training and Physical Functioning in Head and Neck Cancer Patients
University of Alabama at Birmingham
NCT02897375 COMPLETED
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Emory University
NCT03735628 COMPLETED
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
Bayer
NCT05395052 TERMINATED
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
NCT04601402 COMPLETED
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company
NCT04452214 COMPLETED
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
NCT03829436 COMPLETED
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT04440943 COMPLETED
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Celldex Therapeutics
NCT04348916 TERMINATED
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Oncorus, Inc.
NCT02575404 COMPLETED
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
Providence Health & Services
NCT03733210 COMPLETED
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Andrei Iagaru
NCT03841110 COMPLETED
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT04043104 COMPLETED
A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia
MeiraGTx UK II Ltd
NCT05220748 WITHDRAWN
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC
Rakuten Medical, Inc.
NCT03758781 COMPLETED
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT04413214 COMPLETED
Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial
Shanghai Jiao Tong University School of Medicine
NCT03849469 COMPLETED
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Xencor, Inc.
NCT04837677 COMPLETED
A Study of PRT1419 in Patients With Advanced Solid Tumors
Prelude Therapeutics
NCT03689192 COMPLETED
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Herlev Hospital
NCT01846091 COMPLETED
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
Mayo Clinic
NCT02158234 COMPLETED
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
H. Lee Moffitt Cancer Center and Research Institute
NCT04430842 COMPLETED
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
NCT04762225 TERMINATED
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma
Repertoire Immune Medicines
NCT03129061 COMPLETED
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
CellSight Technologies, Inc.
NCT03517488 COMPLETED
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Xencor, Inc.
NCT02764593 COMPLETED
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
RTOG Foundation, Inc.
NCT04060342 TERMINATED
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
NCT01668849 COMPLETED
Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer
University of Louisville
NCT02531906 COMPLETED
Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation
Roswell Park Cancer Institute
NCT04596033 TERMINATED
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
NCT01163487 COMPLETED
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
Daniel T. Chang
NCT02646748 COMPLETED
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
NCT02526017 COMPLETED
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Five Prime Therapeutics, Inc.
NCT00967577 COMPLETED
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Weill Medical College of Cornell University
NCT03319459 COMPLETED
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT03652077 COMPLETED
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT02636036 COMPLETED
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
Akamis Bio
NCT04252248 TERMINATED
Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage
University Hospital Heidelberg
NCT01353625 COMPLETED
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Celgene
NCT03022409 COMPLETED
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
AstraZeneca
NCT02544880 COMPLETED
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC
Donald T. Weed, MD, FACS
NCT02537223 COMPLETED
Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer
University Health Network, Toronto
NCT02201355 TERMINATED
Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck
University of Texas Southwestern Medical Center
NCT03818542 TERMINATED
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
AbbVie
NCT01598077 COMPLETED
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Novartis Pharmaceuticals
NCT03246854 TERMINATED
A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer
National Health Research Institutes, Taiwan
NCT03538028 COMPLETED
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Biosciences International Sàrl
NCT02325401 COMPLETED
Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Cincinnati
NCT01057277 TERMINATED
RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer
howard safran
NCT02576665 TERMINATED
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
NCT02048917 COMPLETED
Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies
University of Kentucky
NCT02686008 WITHDRAWN
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
Yale University
NCT02429089 TERMINATED
Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
NCT03811652 COMPLETED
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
MedImmune LLC
NCT01445405 COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
National Cancer Institute (NCI)
NCT00924092 COMPLETED
An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...
National Cancer Institute (NCI)
NCT02110992 TERMINATED
Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
University of Cincinnati
NCT02124850 TERMINATED
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
Celgene
NCT01758731 COMPLETED
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
University of Colorado, Denver
NCT02473731 COMPLETED
A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
Celldex Therapeutics
NCT00832559 TERMINATED
A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)
Viralytics
NCT01987375 TERMINATED
Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Eben Rosenthal
NCT01017185 COMPLETED
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Takara Bio Inc.
NCT02069158 COMPLETED
Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor
Cristiana Sessa
NCT00978081 COMPLETED
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
Abramson Cancer Center at Penn Medicine
NCT02277197 COMPLETED
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
James J Lee
NCT01716416 COMPLETED
Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Washington University School of Medicine
NCT02565758 COMPLETED
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
AbbVie
NCT02508246 COMPLETED
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
University of Washington
NCT00896350 TERMINATED
MRI in Finding Hypoxia in Patients Undergoing Chemo and Radiation for Head and Neck Cancer
University of Texas Southwestern Medical Center
NCT01871311 TERMINATED
A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
Georgetown University
NCT02205398 TERMINATED
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Novartis Pharmaceuticals
NCT00882583 TERMINATED
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01493154 TERMINATED
Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02960594 COMPLETED
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
Inovio Pharmaceuticals
NCT00675233 COMPLETED
Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx
Roswell Park Cancer Institute
NCT01986426 COMPLETED
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
NCT02350712 COMPLETED
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
Daiichi Sankyo
NCT02543645 TERMINATED
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
NCT00901537 TERMINATED
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
Loma Linda University
NCT02365662 TERMINATED
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
AbbVie
NCT01520389 COMPLETED
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Merrimack Pharmaceuticals
NCT02921984 COMPLETED
Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT01384799 COMPLETED
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Curis, Inc.
NCT01012362 TERMINATED
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT00703638 COMPLETED
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT02216617 COMPLETED
Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy
Groupe Oncologie Radiotherapie Tete et Cou
NCT01721525 COMPLETED
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Memorial Sloan Kettering Cancer Center
NCT02262741 COMPLETED
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer
MedImmune LLC
NCT01727076 COMPLETED
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
National Cancer Institute (NCI)
NCT02211027 WITHDRAWN
Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA
Robert Ferris
NCT02538627 TERMINATED
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
Merrimack Pharmaceuticals
NCT01911598 COMPLETED
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Genentech, Inc.
NCT02251639 WITHDRAWN
Diagnostic Aids for Detection and Diagnosis of Oral Cancer
M.D. Anderson Cancer Center
NCT00937417 WITHDRAWN
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
NCT02567396 WITHDRAWN
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
NCT02110082 COMPLETED
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Bristol-Myers Squibb
NCT00903461 TERMINATED
Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
NCT01046266 COMPLETED
A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma
Hoffmann-La Roche
NCT01451632 COMPLETED
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Merrimack Pharmaceuticals
NCT01975688 TERMINATED
A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis
GW Pharmaceuticals Ltd
NCT00377247 TERMINATED
Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor
University of Pittsburgh
NCT00731380 COMPLETED
A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer
University Health Network, Toronto
NCT01737008 COMPLETED
Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
University Health Network, Toronto
NCT00670397 TERMINATED
Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer
Roswell Park Cancer Institute
NCT01171924 COMPLETED
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
Curis, Inc.
NCT01036412 COMPLETED
Chlorhexidine Gel Therapy for Cariogenic Oral Microflora
M.D. Anderson Cancer Center
NCT00779389 COMPLETED
Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family
University of Pittsburgh
NCT00625456 COMPLETED
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
Jennerex Biotherapeutics
NCT01310179 COMPLETED
Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors
PNP Therapeutics, Inc.
NCT00738751 COMPLETED
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
NCT00968656 COMPLETED
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Washington University School of Medicine
NCT01360827 TERMINATED
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Merck KGaA, Darmstadt, Germany
NCT00918762 COMPLETED
Transoral Robotic Surgery or Standard Surgery in Treating Patients With Benign or Malignant Tumors of the Larynx and Pharynx
Barbara Ann Karmanos Cancer Institute
NCT01255800 COMPLETED
Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer
University of Colorado, Denver
NCT00858663 COMPLETED
Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT01058408 TERMINATED
RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Dana-Farber Cancer Institute
NCT07405086 RECRUITING
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
NCT06162377 RECRUITING
Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.
M.D. Anderson Cancer Center
NCT06879691 ACTIVE NOT RECRUITING
A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma
Biotech Pharmaceutical Co., Ltd.
NCT06807034 ACTIVE NOT RECRUITING
Impact of the Oral Microbiota on Relapse in HNSCC Patients
Institut Sainte Catherine
NCT06734598 RECRUITING
Efficacy of Botox Injection of the Masticatory Muscles in Head &Neck Cancer Patients with Trismus After Radiotherapy
National Taiwan University Hospital
NCT06521697 NOT YET RECRUITING
Effects of Minimal-Flow Sevoflurane and Multimodal Analgesia in Head and Neck Cancer Surgery
National Taiwan University Hospital
NCT05859711 COMPLETED
Effectiveness of Thyme Honey in Management of Xerostomia in Post Radiation Cancer Patients
Ain Shams University
NCT04489888 COMPLETED
A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
Merck Sharp & Dohme LLC
NCT06879366 COMPLETED
Evaluation of the Efficacy of Aloe-Vera el Versus Bezydamine Hydrochloride in the Prevention of Radiation Induced Oral Mucositis A Randamized Controlled Clinical Trial
October 6 University
NCT04977271 WITHDRAWN
Mood Disorders in Head and Neck Cancer Patients
University of Alabama at Birmingham
NCT04246697 COMPLETED
Multimodal Pain Study in Free Flap Patients
University of Kansas Medical Center
NCT02484677 COMPLETED
Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy
Assistance Publique Hopitaux De Marseille
NCT05046028 COMPLETED
Individualization of Nutritive Sensory Support Of Radiation Therapy
National Medical Research Radiological Centre of the Ministry of Health of Russia
NCT05055726 COMPLETED
Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)
Aziende Chimiche Riunite Angelini Francesco S.p.A
NCT04155008 TERMINATED
Nutrition and Pharmacological Algorithm for Oncology Patients Study
Montefiore Medical Center
NCT01553032 COMPLETED
Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)
University of Heidelberg Medical Center
NCT03607227 COMPLETED
Continous Popliteal Block for Microvascular Free Flap Reconstruction in Ear, Nose and Throat Surgery
Region Skane
NCT03714867 WITHDRAWN
Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery
Augusta University
NCT03998696 COMPLETED
An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
NCT02926573 COMPLETED
Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients
Washington University School of Medicine
NCT02049112 COMPLETED
A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study
Unither Pharmaceuticals, France
NCT01418118 COMPLETED
Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
Oxford University Hospitals NHS Trust
Full Head and Neck Cancer Pipeline
Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.
Unlock with ProData: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only